Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718725 | 0.95 | KDM4E (0.44) | DGAT1SOAT1KDM4ELMNAADORA3 | |
| SCHEMBL28275637 | 0.86 | KDM4E (0.42) | DGAT1SOAT1KDM4ELMNAADORA3 | |
| SCHEMBL2124976 | 0.81 | POLB (0.41) | DGAT1SOAT1KDM4ELMNAADORA2A | |
| SCHEMBL30793018 | 0.80 | PDPK1 (0.50) | DGAT1KDM4ELMNAADORA3PKM | |
| SCHEMBL26039163 | 0.80 | PDPK1 (0.50) | DGAT1KDM4ELMNAADORA3PKM | |
| SCHEMBL7135206 | 0.78 | POLB (0.42) | DGAT1SOAT1KDM4EFAAHCHRM2 | |
| SCHEMBL21384412 | 0.78 | DGAT1 (0.36) | DGAT1SOAT1KDM4ELMNAADORA3 | |
| SCHEMBL30591996 | 0.78 | DGAT1 (0.36) | DGAT1SOAT1KDM4ELMNAADORA3 | |
| SCHEMBL2406658 | 0.76 | CA12 (0.48) | CA12CA2CA9CA1 | |
| SCHEMBL29467764 | 0.76 | CA12 (0.48) | CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115485273-A | N- (heterocyclyl and heterocyclylalkyl) -3-benzylpyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-12-16 | — | — | CN | claimed |
| WO-2023072191-A1 | PYRROLOPYRAZOLE SPIRO COMPOUND | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-115485273-A | N- (heterocyclyl and heterocyclylalkyl) -3-benzylpyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-12-16 | — | — | CN | disclosed |
| CN-109069514-A | Antimicrobial compound and application thereof | 结核病药物开发全球联盟公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-105829294-B | The quinolyl conditioning agent of ROR- γ-T being connect with methylene | 詹森药业有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-105848483-A | Quinolinyl modulators of roryt | 詹森药业有限公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-105829294-A | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | 詹森药业有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-103140486-B | Co-crystals and salts of CCR 3-inhibitors | 贝林格尔.英格海姆国际有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | GPBAR1, DGAT1, GPR119 | DGAT1 2/4885SOAT1 11/4885KDM4E 2095/4885 |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | DGAT1, DGAT2, SLC5A1 | DGAT1 1/4885SOAT1 9/4885KDM4E 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.